Gossamer Bio Files New Drug Application for Seralutinib

05:11 PM EDT, 09/23/2026 (MT Newswires) -- Gossamer Bio (GOSS) said late Wednesday it has submitted a new drug application to the US Food and Drug Administration for seralutinib to treat pulmonary arterial hypertension. The FDA will determine whether to accept the filing following its initial review of the application, which could occur later this year, the clinical-stage biopharmaceutical company said.